CLOV CLOVER HEALTH INV CORP

Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement

Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement

FRANKLIN, Tenn., June 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

As previously disclosed, the Company received a written notice from Nasdaq on April 2, 2024, notifying the Company that it had failed to meet the $1.00 per share minimum bid price requirement as part of the Nasdaq Global Select Market’s listing standards.

To regain compliance with the Listing Rule, the Company’s Class A Common Stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on June 25, 2024. Nasdaq has stated that this matter is now closed.

To learn more about Clover Health, visit: .

Forward-Looking Statements

Please note that this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health’s future results of operations, financial position, business strategy and future plans. Forward-looking statements are not guarantees of future performance, and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “going to,” “can,” “could,” “should,” “would,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “outlook,” “forecast,” “guidance,” “objective,” “plan,” “seek,” “grow,” “target,” “if,” “continue,” or the negative of these words or other similar terms or expressions that concern Clover Health’s expectations regarding continued future compliance with Nasdaq listing requirements. These statements are subject to known and unknown risks, uncertainties and other factors that may cause Clover Health’s actual results, levels of activity, performance or achievements to differ materially from results expressed or implied in this press release. Additional information concerning these and other risk factors is contained in Clover Health’s latest Annual Report on Form 10-K filed with the SEC on March 14, 2024, and in our subsequent reports filed with the SEC, in each case, including the Risk Factors section therein, and in its other filings with the SEC. The forward-looking statements included in this press release are made as of the date hereof. Except as required by law, Clover Health undertakes no obligation to update any of these forward-looking statements after the date of this press release or to conform these statements to actual results or revised expectations.

About Clover Health:

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. Clover has published data demonstrating the technology’s impact on , as well as the earlier identification and management of and .

Press Contact:

Andrew Still-Baxter

Investor Relations Contact:

Ryan Schmidt



EN
26/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CLOVER HEALTH INV CORP

 PRESS RELEASE

Clover Health to Participate in Upcoming Leerink 2026 Global Healthcar...

Clover Health to Participate in Upcoming Leerink 2026 Global Healthcare Conference WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Leerink 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 9:20 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at . About Clover Health:Clover Health (Nasdaq: CLOV) i...

 PRESS RELEASE

Clover Health to Report Fourth Quarter and Full Year 2025 Financial Re...

Clover Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter. Fourth Quarter and Full Year 2025 Conference Webcast Detail...

 PRESS RELEASE

Clover Health Announces 53% Growth in Medicare Advantage Membership Du...

Clover Health Announces 53% Growth in Medicare Advantage Membership During AEP, Increasing to 153,000 Members as of January 1, 2026; Expects First-Ever Full Year GAAP Net Income Profitability in 2026 Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income profitability in 2026.Disciplined, core-market growth, strong returning member retention, and improving cohort economics position Clover for compounding earnings and margin expansion.Powered by AI, Clover continues to bring industry-leading clinical quality to...

 PRESS RELEASE

Counterpart Health 2025 Results: How Better Clinical Decisions at Scal...

Counterpart Health 2025 Results: How Better Clinical Decisions at Scale Improve Outcomes, Quality, and Cost Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and financial outcomes SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- , Inc. (“Counterpart” or the “Company”), a leading AI-powered physician-enablement platform and subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), today released key 2025 highlights. The past year was defined by continued publication of research ...

 PRESS RELEASE

Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare C...

Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare Conference WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026, at 11:15 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at . About Clover Health:Clover Health (Nasdaq: CLOV) is a p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch